Podcast Summary: TIP767 – Mastermind Discussion Q4 2025: Sanofi, Remitly & Crocs w/ Stig Brodersen, Tobias Carlisle, Hari Ramachandra

Podcast: We Study Billionaires – The Investor’s Podcast Network
Episode: TIP767
Date: November 9, 2025
Host: Stig Brodersen
Guests: Tobias Carlisle, Hari Ramachandra

Episode Overview

In this Mastermind episode, hosts Stig Brodersen, Tobias Carlisle ("Toby"), and Hari Ramachandra present, critique, and debate three unique investment ideas for Q4 2025:

• Sanofi (biopharmaceutical giant) – pitched by Hari
• Remitly (digital remittance company) – pitched by Stig
• Crocs (global footwear brand) – pitched by Toby

The trio rigorously examines each company’s investment thesis, valuation, risks, and competitive landscape, drawing broader lessons on market cycles and capital allocation. The analysis is detailed with real-world anecdotes and their personal investment philosophies, providing actionable takeaways for value-driven investors.

1. Sanofi – “A Safe Place to Park” (Pitched by Hari Ramachandra)

Time Segment: [01:54 – 18:56]

Thesis Highlights

• Profile: Sanofi is a French-based, global biopharma leader focused on immunology and vaccines.
  • Two main “engines”:
    • Dupixent (anti-inflammatory drug) with decade-long runway
    • Vaccines (recurring, “SaaS-like” revenue stream)
  • Reorganized to focus on core pharma/vaccine strength, with consumer health streamlined
• Valuation:
  • Trades at ~16x PE (below peers e.g., J&J ~25x, Pfizer ~18x)
  • Dividend yield: ~4.9%
  • Buyback of €5 billion planned for 2025
• Why Cheap?
  • EPS “fell off a cliff” in 2023 due to patent expiration (e.g., Aubagio), generic competition, and ramping R&D spend
  • Share price near 52-week lows (“a lot of bad news baked in”)
  • Cyclical underperformance of healthcare sector (vs. Tech/AI)

Key Discussion Points

• Recurring Vaccines Revenue: Compared to SaaS in terms of stickiness and predictability
  • Hari: “Vaccines are really their core strength and a stable source of income. It’s a recurring revenue.”
• Risk & Moat:
  • Biologic exclusivity (patents) + scale/governmental relationships in vaccines
  • Less reliant on single blockbuster vs. peers (e.g., not as “all-in” as Merck on Keytruda) [15:43]
  • Global diversification (Euro-based revenue, USD hedge)
• Market Skepticism:
  • Toby: “I don’t know why healthcare is getting hit so hard right now… maybe it’s just a tech bubble thing, maybe the Covid hangover” [09:42]
  • Hari speculates: Supply chain/tariffs, capital fleeing to AI/Tech, cyclical sector moves

Investment Framing

• “It’s a wealth preservation type move. It’s not a meme stock.” – Stig [22:49]
• Target is safe, moderate returns: 5% dividend + ~3% growth (“like a T-bill with growth attached to it”)
• Opportunity to “park” capital defensively for a decade+, switching to higher-growth opportunities later

Risks

• Regulatory risks, cyclical underperformance, loss of future patents.
• No immediate catalyst for rapid upside; mostly downside protection.

2. Remitly – “Digital Remittance Challenger (But What’s the Moat?)” (Pitched by Stig Brodersen)

Time Segment: [22:49 – 58:15]

Thesis Highlights

• Business: US-based digital remittance platform (RELI ticker), facilitating fast cross-border payments, focusing on the un/underbanked (e.g., migrant workers to the Philippines, Mexico, India)
• Growth:
  • Active users: 8.5 million; 5,000+ “corridors” (e.g., US–Mexico, their largest)
  • Revenue growth: “30-plus percent”; high operational leverage
  • Customer acquisition payback: < 12 months; LTV/CAC ratio ~6x
• Monetization: Transaction fees & FX spreads (~2.24% take rate), membership, new business lines

Key Discussion Points

• Competitive Landscape:
  • Main consumer use-case: “Remitly is for migrant workers… Wise is more small-business, B2B focused.”
  • Sticky, but not “cloud provider sticky”; switching costs moderate, but inertia exists.
  • Local market nuance crucial (e.g., mobile wallet integration in the Philippines, GCash/Maya)
  • Alternatives: Stablecoins? “Regulation, local resistance… it’s not that simple” [32:34]
• Moat/Defensibility Questions:
  • Hari: “There is no network effect… what’s their moat?” [38:02]
  • Stig: “Payments are tricky… if I put on the bull hat, they both have scale and have that specific focus… but now they’re shifting strategy to broader neo-banking, I’m less excited.” [41:09]
  • Product and price can be copied; regulation can stymie disruptors in emerging markets.

Valuation

• “PE over 200” due to inflection point of just reaching positive profitability (not yet normalized) [40:08]
• “2x revenue, no margins… you have to normalize it… I think it trades at a 50% discount to intrinsic value but with lots of assumptions and heavy risks.” [44:45]
• Heavy stock-based compensation (~10% of revenue), a major flag for dilution of shareholders.

Risks/Concerns

• Dilutive stock comp; debate on whether equity-based pay truly incentivizes “owner thinking”
  • Stig: “As a business owner, I could not disagree more… if you have thousands of people… does it really make you think like an owner?” [50:45]
  • Hari (Silicon Valley perspective): “It’s a bidding war for talent… dilution is pervasive, especially when growth ‘cures all sins.’” [52:20]
• Competitive intensity (“borderline venture”), risk that it overextends into less-defensible business lines
• “If they stick to dominating remittances, the opportunity is clear. If they try to be a neo-bank, the waters get murky.” – [paraphrased Stig]

3. Crocs – “Ugly Shoes, Beautiful Numbers” (Pitched by Toby Carlisle)

Time Segment: [58:21 – 77:04]

Thesis Highlights

• Profile: Global casual footwear brand, infamous for “ugly but comfortable” clogs
  • Market cap $4.3B, trading at 6x earnings, 21% free cash flow yield, reporting ~$1B FCF/year
  • $1.3B buyback program in place (25% of shares at current prices)
  • Resilient international growth (16% overall, 64% in China Q2 2025), US remains mainstay
• Track Record: Stock more than halved since ’22 ($180 → $79), even as business continued to grow [58:21]
• Fashion Risks: Brand experienced severe cyclicality (once fell from $67 to $1/share), has rebounded by refocusing on core
  • Toby: “It’s traded like a net-net at times… but also had booms.”
• Valuation: “It’s throwing off so much cash… a little over 1.6x FCF… covers their modest net debt with ease.”

Key Discussion Points

• Risks:
  • Acquisition Overreach: Bought “Hey Dude” for $2.5B—so far, a disappointment, with $700M+ in impairment [71:15]
    • Stig: “Does management have an acquisition problem? Or just a one-off?”
  • Fashion/Coolness Risk: Faddish brand (success on TikTok today, but that rarely lasts)
    • Stig: “I already need to think about selling the minute I buy in… you must watch if it stays cool.”
  • Tariff Exposure: All manufacturing in Asia—big unknowns, threatens lucrative margins
    • Toby: “Once companies know the rules, they will solve for them; uncertainty is the real pain.” [70:08]
• Moat & Copycats:
  • Despite lack of patent defensibility (old, idea easily copied), brand, comfort, and established channel presence maintain edge. Alternatives (e.g., Natives, Birkenstock) haven’t displaced them.
    • Hari: “With microchips being copied, Crocs still has a lead—deserves a premium for that!” [69:08]

Investment Framing

• “If you want certainty, go with Sanofi. If you want volatility and upside, go with Crocs.” – Toby [62:05]
• “Numbers are just too good to ignore… risk is knowing when to exit.” – Stig [75:27]
• Buyback and well-covered debt provide downside protection
• If macro/fashion headwinds reverse, opportunity for rapid multiple re-rating (optionality for a big “win”)

Notable Quotes & Highlights

• On Pharma Valuation:
  • Hari [15:43]: “There is no risk of AI coming in and impacting them so much. If anything, AI can be a tailwind for drug discovery… But in the end, the big buy up the small. The big stay big.”
• On Competitive Flows:
  • Toby [12:15]: “Not enough meme-ability in the healthcare stuff… They’re just consistent, but no chance to go crazy like AI names.”
• On Stock Comp & Dilution:
  • Stig [50:45]: “If you’re thousands of people, does [stock comp] really make you think like an owner? I don’t think so.”
  • Hari [52:20]: “There’s a bidding war for talent… It’s supply and demand. Sometimes companies do it just to keep stars on the bench so competitors don’t get them.”
• On Crocs’ Fashion Risk:
  • Stig [75:50]: “BNSF is not a cool company, but it doesn’t matter. With Crocs you already have to think about selling the day you buy.”
  • Toby [76:33]: “If the business is in decline, you’ve got a lot of time to figure it out—it’s throwing off a billion in FCF.”
• On Investment Process:
  • Stig [44:45]: “I do a bull, a base, and a bear case, but the tricky part is putting probabilities on those, and the conviction in being diluted is often higher than the conviction in continued growth.”

Timestamps for Main Segments

• Sanofi Pitch (Hari): [01:54 – 18:56]

• Deep dive into pharma value, sector rotation, defensive investing, R&D risk, layering international exposure.

• Remitly Pitch (Stig): [22:49 – 58:15]

• Fintech competition, product-market fit, real user stories, dilution, scalable growth vs. defensibility.

• Crocs Pitch (Toby): [58:21 – 77:04]

• Fashion cyclicality, buybacks, valuation, acquisition mistakes, managing “hot” brands, monitoring exit triggers.

Final Thoughts & Mastermind Community

• Impact of Macro Cycles: Panel reflects on the rotation from AI/tech favorites to forgotten value sectors (healthcare, energy, durable consumer brands).
• Community Invitation: New in-person events in Montana and NYC, emphasis on real-world connections for investment networking (details at theinvestorspodcast.com/mastermind)
  • Omaha event for Berkshire Hathaway shareholders highlighted; practical networking insights.

Actionable Takeaways

• In a high-multiple market, defensive non-cyclical sectors (like pharma) offer wealth preservation and moderate upside.
• Rapidly growing fintech requires fierce due diligence: focus on margins, dilution, and true barriers to entry.
• Cheap, high free-cash-flow cyclicals (like Crocs) can be big winners, but demand tight monitoring and risk-management discipline.

For further details and show notes, visit theinvestorspodcast.com.

“The Mastermind format keeps me grounded and curious as an investor. I hope it does the same for you.” – Stig Brodersen [00:03]